CRDF vs. BCAB, SCLX, CRDL, MOLN, VXRT, VCXB, DBVT, CLLS, GNFT, and VIGL
Should you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include BioAtla (BCAB), Scilex (SCLX), Cardiol Therapeutics (CRDL), Molecular Partners (MOLN), Vaxart (VXRT), 10X Capital Venture Acquisition Corp. III (VCXB), DBV Technologies (DBVT), Cellectis (CLLS), Genfit (GNFT), and Vigil Neuroscience (VIGL). These companies are all part of the "biological products, except diagnostic" industry.
BioAtla (NASDAQ:BCAB) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.
BioAtla has a net margin of 0.00% compared to BioAtla's net margin of -6,594.92%. BioAtla's return on equity of -54.54% beat Cardiff Oncology's return on equity.
BioAtla has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 2.02, meaning that its stock price is 102% more volatile than the S&P 500.
In the previous week, Cardiff Oncology had 2 more articles in the media than BioAtla. MarketBeat recorded 9 mentions for Cardiff Oncology and 7 mentions for BioAtla. Cardiff Oncology's average media sentiment score of 0.87 beat BioAtla's score of 0.71 indicating that BioAtla is being referred to more favorably in the media.
Cardiff Oncology has higher revenue and earnings than BioAtla. Cardiff Oncology is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.
BioAtla presently has a consensus price target of $11.00, suggesting a potential upside of 321.46%. Cardiff Oncology has a consensus price target of $10.50, suggesting a potential upside of 193.30%. Given Cardiff Oncology's higher possible upside, research analysts plainly believe BioAtla is more favorable than Cardiff Oncology.
Cardiff Oncology received 16 more outperform votes than BioAtla when rated by MarketBeat users. However, 66.67% of users gave BioAtla an outperform vote while only 62.30% of users gave Cardiff Oncology an outperform vote.
77.2% of BioAtla shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 11.5% of BioAtla shares are owned by insiders. Comparatively, 6.3% of Cardiff Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
BioAtla beats Cardiff Oncology on 9 of the 17 factors compared between the two stocks.
Get Cardiff Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRDF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiff Oncology Competitors List
Related Companies and Tools
